메뉴 건너뛰기




Volumn 29, Issue 5, 2008, Pages 385-394

Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

EID: 42549110110     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/587155     Document Type: Article
Times cited : (28)

References (54)
  • 1
    • 0031585940 scopus 로고    scopus 로고
    • Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
    • (1997) MMWR Recomm Rep , vol.46 , pp. 1-24
  • 2
    • 0035006585 scopus 로고    scopus 로고
    • Pneumococcal disease in the elderly: What is preventing vaccine efficacy?
    • Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 2001; 18:305-311.
    • (2001) Drugs Aging , vol.18 , pp. 305-311
    • Rubins, J.B.1    Janoff, E.N.2
  • 3
  • 4
    • 0038470983 scopus 로고    scopus 로고
    • Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
    • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-968.
    • (2003) Ann Intern Med , vol.138 , pp. 960-968
    • Sisk, J.E.1    Whang, W.2    Butler, J.C.3    Sneller, V.P.4    Whitney, C.G.5
  • 5
    • 42549120339 scopus 로고    scopus 로고
    • Available at:, Accessed September 30, 2007
    • Centers for Disease Control and Prevention - National Center for Health Statistics. NCHS-NHIS data from the January-September 2005 National Health Interview Survey. 2006. Available at: http://www.cdc.gov/nchs/about/major/nhis/ released200603.htm#4. Accessed September 30, 2007.
    • (2006) NCHS-NHIS data from the January-September 2005 National Health Interview Survey
  • 6
    • 42549093715 scopus 로고    scopus 로고
    • US Department of Health and Human Services. Healthy People 2010 1: Understanding and Improving Health and 2: Objectives for Improving Health. 2nd ed. Washington, DC: US Government Printing Office; 2000.
    • US Department of Health and Human Services. Healthy People 2010 Vol. 1: Understanding and Improving Health and Vol. 2: Objectives for Improving Health. 2nd ed. Washington, DC: US Government Printing Office; 2000.
  • 7
    • 0013225804 scopus 로고    scopus 로고
    • Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials
    • Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Family Practice 2000; 1:1.
    • (2000) BMC Family Practice , vol.1 , pp. 1
    • Moore, R.A.1    Wiffen, P.J.2    Lipsky, B.A.3
  • 8
    • 33645773652 scopus 로고    scopus 로고
    • Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia
    • Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093-1101.
    • (2006) Clin Infect Dis , vol.42 , pp. 1093-1101
    • Fisman, D.N.1    Abrutyn, E.2    Spaude, K.A.3    Kim, A.4    Kirchner, C.5    Daley, J.6
  • 9
    • 0020160640 scopus 로고
    • Hospital-based pneumococcal immunization: The epidemiologic rationale and its implementation
    • Fedson DS. Hospital-based pneumococcal immunization: the epidemiologic rationale and its implementation. Infect Control 1982; 3:303-308.
    • (1982) Infect Control , vol.3 , pp. 303-308
    • Fedson, D.S.1
  • 10
    • 0026042704 scopus 로고
    • The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
    • Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-1460.
    • (1991) N Engl J Med , vol.325 , pp. 1453-1460
    • Shapiro, E.D.1    Berg, A.T.2    Austrian, R.3
  • 11
    • 2442677289 scopus 로고    scopus 로고
    • Advisory Committee on Immunization Practices. Use of standing orders programs to increase adult vaccination rates
    • McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE, Advisory Committee on Immunization Practices. Use of standing orders programs to increase adult vaccination rates. MMWR Recomm Rep 2000; 49:15-16.
    • (2000) MMWR Recomm Rep , vol.49 , pp. 15-16
    • McKibben, L.J.1    Stange, P.V.2    Sneller, V.P.3    Strikas, R.A.4    Rodewald, L.E.5
  • 12
    • 8544283806 scopus 로고    scopus 로고
    • Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates
    • Dexter PR, Perkins SM, Maharry KS, Jones K, McDonald CJ. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates. JAMA 2004; 292:2366-2371.
    • (2004) JAMA , vol.292 , pp. 2366-2371
    • Dexter, P.R.1    Perkins, S.M.2    Maharry, K.S.3    Jones, K.4    McDonald, C.J.5
  • 13
    • 14844355721 scopus 로고    scopus 로고
    • Characteristics of long-term care facilities with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states
    • Shefer A, McKibben L, Bardenheier B, Bratzler D, Roberts H. Characteristics of long-term care facilities with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states. J Am Med Dir Assoc 2005; 6:97-104.
    • (2005) J Am Med Dir Assoc , vol.6 , pp. 97-104
    • Shefer, A.1    McKibben, L.2    Bardenheier, B.3    Bratzler, D.4    Roberts, H.5
  • 14
    • 33846813625 scopus 로고    scopus 로고
    • Impact of two different models on influenza and pneumococcal vaccination in hospitalized patients
    • Bakare M, Shrivastava R, Jeevanantham V, Navaneethan SD. Impact of two different models on influenza and pneumococcal vaccination in hospitalized patients. South Med J 2007; 100:140-144.
    • (2007) South Med J , vol.100 , pp. 140-144
    • Bakare, M.1    Shrivastava, R.2    Jeevanantham, V.3    Navaneethan, S.D.4
  • 15
    • 33846228479 scopus 로고    scopus 로고
    • Cost-effectiveness of hospital vaccination programs in North Carolina
    • Honeycutt AA, Coleman MS, Anderson WL, Wirth KE. Cost-effectiveness of hospital vaccination programs in North Carolina. Vaccine 2007; 25:1484-1496.
    • (2007) Vaccine , vol.25 , pp. 1484-1496
    • Honeycutt, A.A.1    Coleman, M.S.2    Anderson, W.L.3    Wirth, K.E.4
  • 16
    • 85136427856 scopus 로고    scopus 로고
    • Sisk J, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people [published correction appears in JAMA 2000; 283:341]. JAMA 1997; 278:1333-1339.
    • Sisk J, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people [published correction appears in JAMA 2000; 283:341]. JAMA 1997; 278:1333-1339.
  • 17
    • 0037009882 scopus 로고    scopus 로고
    • Medicare and Medicaid programs; conditions of participation: Immunization standards for hospitals, long-term care facilities, and home health agencies: final rule with comment period
    • Centers for Medicare and Medicaid Series H
    • Centers for Medicare and Medicaid Series H. Medicare and Medicaid programs; conditions of participation: immunization standards for hospitals, long-term care facilities, and home health agencies: final rule with comment period. Fed Reg 2002; 67:61808-61814.
    • (2002) Fed Reg , vol.67 , pp. 61808-61814
  • 19
    • 0142089731 scopus 로고    scopus 로고
    • Designing a hospital-based pneumococcal vaccination program
    • Skledar SJ, Hess MM, Ervin KA, et al. Designing a hospital-based pneumococcal vaccination program. Am J Health Syst Pharm 2003; 60:1471-1476.
    • (2003) Am J Health Syst Pharm , vol.60 , pp. 1471-1476
    • Skledar, S.J.1    Hess, M.M.2    Ervin, K.A.3
  • 20
    • 42549128864 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Self-reported pneumococcal vaccination coverage trends 1989-2005 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Available at: http://www.cdc.gov/flu/ professionals/vaccination/pdf/pneumococcal-vaccinetrend.pdf. Accessed September 30, 2007.
    • Centers for Disease Control and Prevention. Self-reported pneumococcal vaccination coverage trends 1989-2005 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Available at: http://www.cdc.gov/flu/ professionals/vaccination/pdf/pneumococcal-vaccinetrend.pdf. Accessed September 30, 2007.
  • 21
    • 0037163462 scopus 로고    scopus 로고
    • Pneumococcal vaccination: Analysis of opportunities in an inner-city hospital
    • Husain S, Slobodkin D, Weinstein RA. Pneumococcal vaccination: analysis of opportunities in an inner-city hospital. Arch Intern Med 2002; 162:1961-1965.
    • (2002) Arch Intern Med , vol.162 , pp. 1961-1965
    • Husain, S.1    Slobodkin, D.2    Weinstein, R.A.3
  • 22
    • 33749351792 scopus 로고    scopus 로고
    • Influenza and pneumococcal vaccination coverage among persons aged > or = 65 years - United States, 2004-2005
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged > or = 65 years - United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2006; 55:1065-1068.
    • (2006) MMWR Morb Mortal Wkly Rep , vol.55 , pp. 1065-1068
  • 23
    • 0006873196 scopus 로고    scopus 로고
    • Available at:, Accessed September 30, 2007
    • Agency for Healthcare Research and Quality. Healthcare Cost & Utilization Project (HCUP). 2003. Available at: http://www.ahrq.gov/data/hcup/. Accessed September 30, 2007.
    • (2003) Healthcare Cost & Utilization Project (HCUP)
  • 24
    • 27244440305 scopus 로고    scopus 로고
    • Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine
    • Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051.
    • (2005) JAMA , vol.294 , pp. 2043-2051
    • Lexau, C.A.1    Lynfield, R.2    Danila, R.3
  • 25
    • 0035825293 scopus 로고    scopus 로고
    • Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines
    • Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med 2001; 161:111-120.
    • (2001) Arch Intern Med , vol.161 , pp. 111-120
    • Weaver, M.1    Krieger, J.2    Castorina, J.3    Walls, M.4    Ciske, S.5
  • 26
    • 0035804857 scopus 로고    scopus 로고
    • Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era
    • Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-1735.
    • (2001) JAMA , vol.285 , pp. 1729-1735
    • Robinson, K.A.1    Baughman, W.2    Rothrock, G.3
  • 31
    • 0038470983 scopus 로고    scopus 로고
    • Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
    • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-968.
    • (2003) Ann Intern Med , vol.138 , pp. 960-968
    • Sisk, J.E.1    Whang, W.2    Butler, J.C.3    Sneller, V.P.4    Whitney, C.G.5
  • 32
    • 0033585453 scopus 로고    scopus 로고
    • Safety of revaccination with pneumococcal polysaccharide vaccine
    • Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281:243-248.
    • (1999) JAMA , vol.281 , pp. 243-248
    • Jackson, L.A.1    Benson, P.2    Sneller, V.P.3
  • 33
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481.
    • (1992) CMAJ , vol.146 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 34
    • 0028046941 scopus 로고
    • Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization
    • Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-952.
    • (1994) Ann Intern Med , vol.121 , pp. 947-952
    • Mullooly, J.P.1    Bennett, M.D.2    Hornbrook, M.C.3
  • 35
    • 0028048820 scopus 로고
    • The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
    • Nichol KL, Margolis KL, Wuorenma J, Von Sternberg TL. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-784.
    • (1994) N Engl J Med , vol.331 , pp. 778-784
    • Nichol, K.L.1    Margolis, K.L.2    Wuorenma, J.3    Von Sternberg, T.L.4
  • 36
    • 34248230801 scopus 로고    scopus 로고
    • Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    • Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-1288.
    • (2007) Clin Infect Dis , vol.44 , pp. 1280-1288
    • Rothberg, M.B.1    Virapongse, A.2    Smith, K.J.3
  • 37
    • 33749048487 scopus 로고    scopus 로고
    • Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    • Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317-325.
    • (2006) Ann Intern Med , vol.145 , pp. 317-325
    • Hornberger, J.1    Robertus, K.2
  • 38
    • 16544388321 scopus 로고    scopus 로고
    • Adult immunization programs in nontraditional settings: Quality standards and guidance for program evaluation
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. MMWR Morbid Mortal Wkly Rep 2000; 49(RR-01):1-13.
    • (2000) MMWR Morbid Mortal Wkly Rep , vol.49 , Issue.RR-01 , pp. 1-13
  • 39
    • 27944475568 scopus 로고    scopus 로고
    • Overcoming barriers to establishing an inpatient vaccination program for pneumococcus using standing orders
    • Middleton DB, Fox DE, Nowalk MP, et al. Overcoming barriers to establishing an inpatient vaccination program for pneumococcus using standing orders. Infect Control Hosp Epidemiol 2005; 26:874-881.
    • (2005) Infect Control Hosp Epidemiol , vol.26 , pp. 874-881
    • Middleton, D.B.1    Fox, D.E.2    Nowalk, M.P.3
  • 40
    • 26444552099 scopus 로고    scopus 로고
    • Policies to increase influenza and pneumococcal immunizations in chronically ill and institutionalized settings
    • Goldstein AO, Kincade JE, Resnick JE, Gamble G, Bearman RS. Policies to increase influenza and pneumococcal immunizations in chronically ill and institutionalized settings. Am J Infect Control 2005; 33:463-468.
    • (2005) Am J Infect Control , vol.33 , pp. 463-468
    • Goldstein, A.O.1    Kincade, J.E.2    Resnick, J.E.3    Gamble, G.4    Bearman, R.S.5
  • 41
    • 34249082853 scopus 로고    scopus 로고
    • Designing and implementing a hospital-based vaccine standing orders program
    • Sokos D, Skledar S, Ervin K, et al. Designing and implementing a hospital-based vaccine standing orders program. Am J Health Syst Pharm 2007; 64:1096-1102.
    • (2007) Am J Health Syst Pharm , vol.64 , pp. 1096-1102
    • Sokos, D.1    Skledar, S.2    Ervin, K.3
  • 42
    • 42549100054 scopus 로고    scopus 로고
    • Lindley M, Shefer A, and Shaw F. Assessing state immunization requirements for healthcare workers and patients. In: Program and abstracts of the 40th National Immunization Conference; 2006; Atlanta, GA.
    • Lindley M, Shefer A, and Shaw F. Assessing state immunization requirements for healthcare workers and patients. In: Program and abstracts of the 40th National Immunization Conference; 2006; Atlanta, GA.
  • 43
    • 37349009553 scopus 로고    scopus 로고
    • Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine PCV7 serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004
    • Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine PCV7 serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-1354.
    • (2007) J Infect Dis , vol.196 , pp. 1346-1354
    • Hicks, L.A.1    Harrison, L.H.2    Flannery, B.3
  • 44
    • 0022896971 scopus 로고
    • Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans Administration Cooperative Study
    • Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-1327.
    • (1986) N Engl J Med , vol.315 , pp. 1318-1327
    • Simberkoff, M.S.1    Cross, A.P.2    Al-Ibrahim, M.3
  • 45
    • 0027887335 scopus 로고
    • Pneumococcal vaccination in the prevention of community-acquired pneumonia: An optimistic view of cost-effectiveness
    • Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1993; 8:285-293.
    • (1993) Semin Respir Infect , vol.8 , pp. 285-293
    • Fedson, D.S.1
  • 46
    • 0022645087 scopus 로고
    • Cost effectiveness of vaccination against pneumococcal pneumonia: An update
    • Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104:79-86.
    • (1986) Ann Intern Med , vol.104 , pp. 79-86
    • Sisk, J.E.1    Riegelman, R.K.2
  • 47
    • 0025695549 scopus 로고
    • Pneumococcal vaccine: Efficacy and associated cost savings
    • Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990; 264:2910-2915.
    • (1990) JAMA , vol.264 , pp. 2910-2915
    • Gable, C.B.1    Holzer, S.S.2    Engelhart, L.3
  • 48
    • 0019379183 scopus 로고
    • A cost-benefit analysis of immunization for pneumococcal pneumonia
    • Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981; 245:473-477.
    • (1981) JAMA , vol.245 , pp. 473-477
    • Patrick, K.M.1    Woolley, F.R.2
  • 49
    • 0018959705 scopus 로고
    • Cost effectiveness of vaccination against pneumococcal pneumonia
    • Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303:553-559.
    • (1980) N Engl J Med , vol.303 , pp. 553-559
    • Willems, J.S.1    Sanders, C.R.2    Riddiough, M.A.3    Bell, J.C.4
  • 50
    • 3242885700 scopus 로고    scopus 로고
    • Economic aspects of pneumococcal pneumonia: A review of the literature
    • DeGraeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004; 22:719-740.
    • (2004) Pharmacoeconomics , vol.22 , pp. 719-740
    • DeGraeve, D.1    Beutels, P.2
  • 51
    • 0034101109 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium
    • DeGraeve D, Lombaert G, Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. Pharmacoeconomics 2000; 17:591-601.
    • (2000) Pharmacoeconomics , vol.17 , pp. 591-601
    • DeGraeve, D.1    Lombaert, G.2    Goossens, H.3
  • 52
    • 0242600542 scopus 로고    scopus 로고
    • Effectiveness of pneumococcal polysaccharide vaccine in older adults
    • Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755.
    • (2003) N Engl J Med , vol.348 , pp. 1747-1755
    • Jackson, L.A.1    Neuzil, K.M.2    Yu, O.3
  • 53
    • 0028075609 scopus 로고
    • Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials
    • Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-2677.
    • (1994) Arch Intern Med , vol.154 , pp. 2666-2677
    • Fine, M.J.1    Smith, M.A.2    Carson, C.A.3
  • 54
    • 20444390513 scopus 로고    scopus 로고
    • Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska
    • Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005; 40:1730-1735.
    • (2005) Clin Infect Dis , vol.40 , pp. 1730-1735
    • Walker, F.J.1    Singleton, R.J.2    Bulkow, L.R.3    Strikas, R.A.4    Butler, J.C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.